Summary & Overview
HCPCS J1265: Injection, Dopamine HCl 40 mg
HCPCS Level II code J1265 denotes an injectable formulation: dopamine hydrochloride 40 mg. This code is used to bill administration of dopamine for hemodynamic support in acute care settings and is relevant across inpatient and closely monitored outpatient infusion contexts. Nationally, vasoactive agents like dopamine are critical in management of shock and hypotension, making accurate coding essential for clinical documentation and payment.
Key payers included in this coverage analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for J1265, how the service is typically delivered, benchmark considerations for utilization, and relevant policy and billing points that influence claims processing. The publication highlights common sites of service, typical clinical indications, and factors payers review when adjudicating claims for parenteral vasoactive medications.
The report provides practical information for billing teams, revenue cycle professionals, and compliance officers seeking clarity on coding and payer expectations related to dopamine injection. Data not provided in the input, such as payer-specific reimbursement rates, allowed diagnoses, and utilization statistics, are noted as unavailable where applicable.
Billing Code Overview
HCPCS Level II code J1265 represents injection, dopamine hcl, 40 mg, a parenteral medication administration used to provide dopamine for hemodynamic support. The service type is a drug injection/infusion medication given intravenously. The typical site of service is an inpatient hospital setting or other acute care facility where continuous hemodynamic monitoring and vasoactive drug administration occur.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult hospitalized for septic shock, cardiogenic shock, or severe hypotension unresponsive to fluid resuscitation and initial vasopressor therapy. The patient is monitored in an intensive care unit (ICU) or emergency department (ED) setting with continuous cardiac and hemodynamic monitoring. An advanced practice provider or physician assesses the need for inotropic support; dopamine is selected when inotropic and vasopressor effects are required at moderate doses. The medication J1265 (injection, dopamine HCl, 40 mg) is obtained from pharmacy, prepared under aseptic conditions, and administered through a central venous catheter or peripheral IV per facility policy. Vital signs, urine output, and vasoactive infusion rates are titrated to achieve target mean arterial pressure and end-organ perfusion. Documentation includes indication, dose and concentration administered, route, start and stop times, patient response, and any adverse effects such as arrhythmia or ischemia. Billing captures the HCPCS Level II code J1265 for the administered drug, along with appropriate service and place-of-service coding for the ICU, ED, or inpatient setting.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Default when no other modifier applies |